Charcot-Marie-Tooth disease type 1. Molecular pathogenesis to gene therapy

John Kamholz*, Daniela Menichella, Agnes Jani, James Garbern, Richard A. Lewis, Karen M. Krajewski, Jack Lilien, Steven S. Scherer, Michael E. Shy

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

73 Scopus citations


Charcot-Marie-Tooth disease type 1 (CMT1) is caused by mutations in the peripheral myelin protein, 22 kDa (PMP22) gene, protein zero (P0) gene, early growth response gene 2 (EGR-2) and connexin-32 gene, which are expressed in Schwann cells, the myelinating cells of the peripheral nervous system. Although the clinical and pathological phenotypes of the various forms of CMT1 are similar, including distal muscle weakness and sensory loss, their molecular pathogenesis is likely to be quite distinct. In addition, while demyelination is the hallmark of CMT1, the clinical signs and symptoms of the disease are probably produced by axonal degeneration, not demyelination itself. In this review we discuss the molecular pathogenesis of CMT1, as well as approaches to an effective gene therapy for this disease.

Original languageEnglish (US)
Pages (from-to)222-233
Number of pages12
Issue number2
StatePublished - Feb 2000


  • CMT
  • Gene therapy
  • Myelination
  • Schwann cell axonal interactions

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Charcot-Marie-Tooth disease type 1. Molecular pathogenesis to gene therapy'. Together they form a unique fingerprint.

Cite this